Editor, Rebekah Jordan, sat down with Dr. Gen Li, president and co-founder of Phesi, to learn more about how the company’s AI-driven clinical database is allowing insights and observations to be drawn from big clinical trial data.
Key insights:
- AI can ensure that all aspects of a clinical trial are in sync, giving a higher level of assurance for success.
- Breast cancer was the most studied clinical area in 2022, despite the fact that the overall clinical trial development activity was declining.
- The number of clinical trial sites only able to recruit a single patient for a particular trial is increasing, with an increasing number of attrition rates.
- Dencentralised trials could minimise some of the issues associated with clinical trials, and may encourage more participants for trials.
Q. Could you tell us about the kind of work Phesi does?
A. Let me start by saying there is nothing more objective than data. The industry has many mechanisms to collect large amounts of data, but they have shown little value to us.